ABSTRACT The bronchodilator potencies of inhaled atropine sulphate and atropine methonitrate have been compared either alone or in combination with fenoterol in a group of adult asthmatic patients. A cumulative dose response study showed that 2 mg of atropine sulphate produced near maximum bronchodilatation. A larger dose of 4 mg was used in comparing the potency of this drug with 2 mg of atropine methonitrate, a dose previously shown to produce optimum bronchodilatation. In a randomised double-blind fashion atropine methonitrate (2 mg), atropine sulphate (4 mg), fenoterol (400 jg), a combination of atropine methonitrate with fenoterol, a combination of atropine sulphate with fenoterol, and two placebos were administered by inhalation on separate days to eight stable adult asthmatics. Measurements of FEV1 were made before administration of the drugs and at 20 minutes, one, two, four, and six hours afterwards. The two atropine drugs produced a similar peak effect but the bronchodilatation after atropine methonitrate was more prolonged. In combination the bronchodilatation achieved with both atropine drugs and fenoterol was greater than with either atropine or fenoterol alone, confirming that atropine and an adrenergic drug can have an additive effect. The response with atropine methonitrate and fenoterol showed a significant increase in the FEV1 for six hours whereas with atropine sulphate and fenoterol the increase of FEV1 was significantly greater than the placebo for only four hours. It was concluded that the atropine drugs produce useful bronchodilatation either alone or in combination with an adrenergic agent. Of the two atropine drugs, the methonitrate appears to be superior to the sulphate as an inhaled bronchodilator in adult asthmatics. 
The anticholinergic drugs atropine sulphate and atropine methonitrate are effective bronchodilators. Moreover, in adults with chronic asthma, optimum doses of atropine methonitrate together with salbutamol produce significantly greater and more lasting bronchodilatation than either drug alone.' Cavanaugh and Cooper2 have reported that provided an adequate dose is used, atropine sulphate by inhalation is a very effective bronchodilator in asthmatic children, but they did not detect any additive effect when isoprenaline was administered concurrently.
The aim of the present study has been to compare the effectiveness of atropine methonitrate with that of atropine sulphate either alone or in combination with the long-acting adienergic agent, fenoterol. Optimal doses of the atropine drugs were compared. The In a randomised, double-blind fashion on six week days (consecutive where possible), the eight patients were given 2 mg atropine methonitrate, 4 mg atropine sulphate, 400 ,ug fenoterol, the combination of atropine methonitrate and fenoterol, the combination of atropine sulphate and fenoterol, or two placebos. Each study started at about 0900 m and followed an identical procedure. A wet aerosol was given followed by two puffs from a pressurised metered dose inhaler. In randomised order the wet aerosol contained a 1 possible dose of atropine sulphate which will produce maximum bronchodilatation, it did show that as a wet aerosol by inhalation a dose of 2 mg is adequate, and a dose of4 mg is more than adequate for this purpose. Consequently the failure of a dose of 4 mg of atropine sulphate to produce bronchodilatation as prolonged as that produced by a dose of 2 mg atropine methonitrate cannot be attributed to an inadequate dose. Instead, it confirms that atropine sulphate is less potent than atropine methonitrate when both are administered by inhalation.
The combination of atropine sulphate with fenoterol produced significantly greater bronchodilatation than either atropine sulphate or fenoterol alone. This result differs from that of Cavanaugh and Cooper2 who did not obtain any additive effect with isoprenaline and atropine sulphate in children. This may be because of the different type of patient or the use of a short-acting adrenergic agent, as an Comparison of inhaled atropine sulphate and atropine methonitrate additive effect has been demonstrated with atropine methonitrate and salbutamol, using optimum doses of each in adult asthmatic patients.' Similarly atropine methonitrate with fenoterol produced greater bronchodilatation than both fenoterol and atropine methonitrate alone in the present study. Our dose-response study ensured that we had an adequate dose of atropine sulphate, and the studies of Shenfield and Paterson3 suggest that the dose of fenoterol used in our study was optimum. Hence, the additive effect demonstrated is unlikely to be the result of suboptimal doses of either drug. It may be related to differences in the pharmacological action of each drug or to differences in receptor sites within the airways. Ingram et a14 have reported that atropine has a relatively greater effect than adrenergic stimulants upon larger airways of normal subjects. However, despite this differentiation, the combined effects of atropine sulphate and isoprenaline were not found to be additive in normal subjects when the drugs were combined. Pharmacological differences between the drugs may be more relevant. It has been shown that beta-adrenergic drugs are functional antagonists of cholinomimetics, such as methacholine, whereas atropine is a competitive antagonist.5 Functional antagonists act through a separate receptor system without changing the receptors of the spasmogen, whereas competitive antagonists inhibit the spasmogen receptors. Because of this difference in action, the effects of atropine and of adrenergic drugs can be additive. This has been demonstrated in the isolated trachea of animals.5 This additive effect using atropine is likely to occur only when bronchoconstriction is through the cholinergic pathway. When spasmogens such as histamine produce bronchoconstriction through other receptors, atropine is unlikely to be an effective bronchodilator. The patients in the present investigation may have been particularly responsive to anticholinergic drugs. They were studied when relatively stable and all those in the drug comparison trial were receiving corticosteroids. Patients with these characteristics are more responsive to anticholinergic drugs than other asthmatics. 6 We have shown that in such patients, both atropine methonitrate and atropine sulphate alone or with fenoterol, produce useful bronchodilatation by inhalation and that the methonitrate is superior to the sulphate. 
